Vitamin D receptor activation and cardiovascular disease (Q38069143)

28 August 2017

1 reference

title

Vitamin D receptor activation and cardiovascular disease (English)

1 reference

28 August 2017

0 references

cardiovascular disease

1 reference

Alberto Ortiz

5

0 references

author name string

Emilio Gonzalez-Parra

1

1 reference

28 August 2017

Jorge Rojas-Rivera

2

1 reference

28 August 2017

Jose Tuñón

3

1 reference

28 August 2017

Manuel Praga

4

1 reference

28 August 2017

Jesus Egido

6

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 December 2012

1 reference

Nephrology Dialysis Transplantation

28 August 2017

1 reference

28 August 2017

27 Suppl 4

1 reference

28 August 2017

iv17-21

1 reference

The noncalciotropic actions of vitamin D: recent clinical developments

28 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

The expanding spectrum of biological actions of vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Cardiovascular calcification in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Vitamin D deficiency and risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Plasma 25-hydroxyvitamin D levels and risk of incident hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Systematic Review: Vitamin D and Cardiometabolic Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

The 2011 IOM report on vitamin D and calcium requirements for north america: clinical implications for providers treating patients with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Impact of kidney bone disease and its management on survival of patients on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Impact of activated vitamin D and race on survival among hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

The effect of vitamin D derivatives on vascular calcification associated with inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Myocardial effects of VDR activators in renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Paricalcitol attenuates cyclosporine-induced kidney injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Differential effects of vitamin D analogs on vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Differential effects of Vitamin D analogs on bone formation and resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

Changes in Serum 25-Hydroxyvitamin D and Plasma Intact PTH Levels Following Treatment With Ergocalciferol in Patients With CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS534

21 January 2018

Identifiers

DOI

10.1093/NDT/GFS534

1 reference

28 August 2017

1 reference